SMMTSummit Therapeutics Inc.

Nasdaq summittxinc.com


$ 20.03 $ 3.93 (24.41 %)    

Monday, 09-Sep-2024 11:37:46 EDT
QQQ $ 452.20 $ -0.33 (-0.07 %)
DIA $ 409.37 $ 2.04 (0.5 %)
SPY $ 545.03 $ 0.36 (0.07 %)
TLT $ 99.73 $ 0.35 (0.35 %)
GLD $ 230.70 $ -0.56 (-0.24 %)
$ 12.27
$ 16.10
$ 19.00 x 300
$ 20.07 x 100
$ 15.61 - $ 21.44
$ 1.52 - $ 14.25
2,090,407
na
8.89B
$ -0.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-01-2024 03-31-2024 10-Q
3 02-20-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-17-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-buy-on-summit-therapeutics-raises-price-target-to-19

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...

 stifel-maintains-buy-on-summit-therapeutics-raises-price-target-to-25

Stifel analyst Bradley Canino maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $14 to...

Core News & Articles

PLTR: 8% | Palantir Technologies shares are trading higher amid its addition to the S&P 500 index. TERN: 42% | Terns Pharma...

 summit-therapeutics-lung-cancer-candidate-surpasses-mercks-multi-billion-dollar-keytruda-cuts-risk-of-disease-or-death-by-half

Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free sur...

 hc-wainwright--co-maintains-buy-on-summit-therapeutics-raises-price-target-to-30

HC Wainwright & Co. analyst Mitchell Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price ...

Core News & Articles

 Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First...

 hc-wainwright--co-reiterates-buy-on-summit-therapeutics-maintains-16-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $16 pr...

 hc-wainwright--co-reiterates-buy-on-summit-therapeutics-maintains-16-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $16 pr...

 hc-wainwright--co-reiterates-buy-on-summit-therapeutics-maintains-16-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $16 pr...

 hc-wainwright--co-reiterates-buy-on-summit-therapeutics-maintains-16-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $16 pr...

 hc-wainwright--co-initiates-coverage-on-summit-therapeutics-with-buy-rating-announces-price-target-of-16

HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating an...

 summit-therapeutics-q2-2024-adj-eps-005-beats-006-estimate-cash-and-equivalents-of-3258m

Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $...

 xpeng--quantumscape-are-among-top-11-mid-cap-stocks-that-performed-well-last-week-july-7-july-13-details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeut...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION